Thank you, Eilif. As a reminder, campus-based higher education is a seasonal business. Although the third quarter is a large intake period, from a P&L perspective, it is seasonally low, as classes are out of session for much of the quarter. Let's start with Pages 10 and 11, which highlight our operating and financial performance for the third quarter and year-to-date. New enrollments and total enrollments were both up 6% for the quarter when compared to the prior year period. Pricing at a brand and degree level was in line with expectations, and when combined with year-to-date volume performance, is covering our implied cost of inflation as anticipated. During the recent intake, we did experience a positive mix impact on average revenue per student versus expectations, primarily driven by Mexico. Revenue in the third quarter was $362 million, and adjusted EBITDA was $78 million. On an organic constant currency basis, revenue for the third quarter increased 8% year-over-year. Adjusted EBITDA declined slightly year-over-year, and was in line with the guidance range we provided for the quarter's performance. The decrease was attributable to the shifting of expenses from the first half of the year, as discussed on our prior call, and additional costs related to lease exits, as we continue to focus on optimization of the real estate footprint in Mexico. When combined with the first half, and still on an organic constant currency basis, our overall performance for the nine months ended in 2023 resulted in revenue growth of 11%, and adjusted EBITDA increase of 10%. Let me now provide some additional color on the performance of Mexico and Peru, starting with Page 13. Please note that all comparisons versus prior year are on an organic and constant currency basis. Let's start with Mexico. We are very pleased with Mexico's primary intake performance. As a reminder, Mexico grew new enrollment 17% in last year's primary intake. We signaled in our previous calls that this would create a hard comparison in the second half of this year, but that we still expected to deliver year-over-year growth during the intake. That growth came in as new enrollments increased 4% timing-adjusted. As Eilif noted, over the past two years, new enrollments have increased 21% in Mexico during its primary intake, driven by double-digit growth in both our premium and value brands, and across both our face-to-face and fully online offerings. For the third quarter, Mexico's revenue grew 6% versus the prior year. Adjusted EBITDA declined $5 million, as expected, due to shifting of expenses referred to earlier and lease exit costs. On a year-to-date basis, revenue growth of 13% was driven by a 10% increase in average total enrollments, and 3% of price mix. Adjusted EBITDA increased 19% year-to-date versus the prior year period, driven by revenue flow-through and productivity gains, partially offset by return-to-campus expenses. We believe that our strategy to expand margins in Mexico to above 25% in the next couple of years is well underway. Let's now transition to Peru on Slide 14. During the smaller intake cycle just completed, new enrollments in Peru increased 2% versus the prior year period, and total enrollments grew 4%. As Eilif noted in his opening remarks, Peru is currently experiencing some pressure on the consumer. Accordingly, we did experience higher attrition during the recently completed secondary intake. The impact was felt across the entire sector. Despite the macroeconomic conditions, we are still delivering strong topline growth due to a solid primary intake earlier in the year, and disciplined pricing approach. For the third quarter, Peru's revenue growth was up 10%. Adjusted EBITDA increased 3%, reflecting the expected impact of return-to-campus expenses, and additional investments in our health science and digital offerings. On a year-to-date basis, revenue growth of 10% was driven by a 6% increase in average total enrollments, and a 4% increase of price mix. Adjusted EBITDA was up 1% versus the prior year-to-date, with the decline in margins, as expected, as incremental revenue flow-through was partially offset by expenses associated with return to face-to-face classes at our campuses. Let me now briefly discuss our balance sheet position. Laureate ended September with $131 million in cash, and $135 million in gross debt, for a net debt position of only $4 million. During the quarter, we refinanced our corporate revolver, extending its maturity through September 2028, while reducing the size of the commitment to be more appropriate for what is needed for our organization post-transformation. Key terms under the revolver, including pricing, were largely unchanged. Our strong balance sheet and extended revolver maturity supported our board’s decision to declare the special cash dividend of $0.70 per share today. Moving on to our updated outlook for 2023, starting on Page 15. We are maintaining revenue and adjusted EBITDA expectations for the full year on a constant currency basis within the previously guided range. However, we have narrowed the range, given only the fourth quarter remains in the year. On the foreign currency component, though still very favorable for the year, FX rates have declined since the time of our second quarter earnings call. As a result, we are reducing the full-year FX benefit to reflect current spot rates. As a reminder, we consistently provide guidance on a spot FX rate basis. During the recent intake, we did experience a positive price and mix impact, but that was offset by higher attrition rates in Peru related to the macroeconomic softness in that market. As a result, we now expect total enrollment volume closer to the low end of our previous range. Based on current spot FX rates, we now expect full-year 2023 results to be as follows; total enrollments to be approximately 447,000 students, reflecting growth of approximately 6% versus 2022, revenue to now be in the range of $1.457 billion to $1.465 billion, reflecting growth of 17% to 18% on an as-reported basis, and 10% on an organic constant currency basis versus 2022, adjusted EBITDA to now be in the range of $410 million to $416 million, reflecting growth of 21% to 23% on an as-reported basis, and 14% to 16% on an organic constant currency basis versus 2022. Now moving to the fourth quarter guidance. For the fourth quarter of 2023, we expect revenue to be in the range of $382 million to $390 million, adjusted EBITDA to be in the range of $123 million to $129 million, with strong margin expansion expected during the fourth quarter. That concludes my prepared remarks. Eilif, I'm handing it back to you for closing comments.